AVB-001 for Ovarian Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests AVB-001, a modified cell product that produces IL-2, in patients with difficult-to-treat ovarian, peritoneal, or fallopian tube cancer. The treatment aims to enhance the immune system's ability to fight cancer. Interleukin-2 (IL-2) has been studied for its potential to improve immune function and has shown promise in treating advanced ovarian cancer.
Will I have to stop taking my current medications?
The trial protocol does not specify if you need to stop taking your current medications. However, if you are on anticoagulation medications, you must be able to pause them for the laparoscopic procedure on Day 1.
What safety data exists for AVB-001 (also known as VB-111) in humans?
What data supports the effectiveness of the treatment AVB-001 for ovarian cancer?
Who Is on the Research Team?
Claudio Dansky Ullmann, MD
Principal Investigator
Avenge Bio, Inc
Claudio Dansky Ullman, MD
Principal Investigator
Avenge Bio, Inc
Are You a Good Fit for This Trial?
This trial is for patients with high-grade serous adenocarcinoma of the ovary, primary peritoneum, or fallopian tube that's resistant to platinum-based chemotherapy. They must have measurable disease and can't have had more than five prior therapies. Those with certain gene mutations need to have progressed after PARP inhibitor therapy.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Dose Escalation
Part 1: Dose Escalation Phase using a Bayesian optimal interval model-assisted design to determine the maximally tolerated dose of AVB-001
Dose Expansion
Part 2: Dose Expansion Phase where a single dose of AVB-001 at the recommended Phase 2 dose is administered to additional patients
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- AVB-001
Find a Clinic Near You
Who Is Running the Clinical Trial?
Avenge Bio, Inc
Lead Sponsor